Clinical Trials Details

EXActDNA-003: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64)

IRB Protocol Number

NSABP B-64

Clinical Trial Categories

• Breast Cancer

Contact

Clinical Trials at 910-715-2200

How to Participate

Eligibility: 

• 18 years of age.
• Invasive carcinoma of the breast.
• Planned chemotherapy.
• Tumor size ≥ 2.1 cm in greatest diameter.
• Unifocal or multifocal cancer documented to be the same
• Histologic clinical subtype.
• Clinically node positive or node negative.